These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33707177)

  • 1. B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis.
    Tacke S; Braune S; Rovituso DM; Ziemssen T; Lehmann PV; Dikow H; Bergmann A; Kuerten S
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33707177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
    Rovituso DM; Duffy CE; Schroeter M; Kaiser CC; Kleinschnitz C; Bayas A; Elsner R; Kuerten S
    Sci Rep; 2015 Sep; 5():14265. PubMed ID: 26387426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
    Boziki M; Lagoudaki R; Melo P; Kanidou F; Bakirtzis C; Nikolaidis I; Grigoriadou E; Afrantou T; Tatsi T; Matsi S; Grigoriadis N
    J Neurol Sci; 2019 Jun; 401():43-50. PubMed ID: 31009931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of peginterferon-β-1a in the real-world practice for relapsing-remitting multiple sclerosis.
    Moccia M; Santoni L; Vaccari I; Affinito G; Caliendo D; Rubba F; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):411-418. PubMed ID: 38235893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disability progression
    von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö
    Mult Scler; 2021 Mar; 27(3):439-448. PubMed ID: 32463336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients.
    Boldrini VO; Marques AM; Quintiliano RPS; Moraes AS; Stella CRAV; Longhini ALF; Santos I; Andrade M; Ferrari B; Damasceno A; Carneiro RPD; Brandão CO; Farias AS; Santos LMB
    Front Immunol; 2022; 13():750660. PubMed ID: 35197967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.
    Spelman T; Frisell T; Piehl F; Hillert J
    Mult Scler; 2018 Jul; 24(8):1087-1095. PubMed ID: 28649912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate.
    Rojas-Morales E; Santos-López G; Hernández-Cabañas S; Arcega-Revilla R; Rosas-Murrieta N; Jasso-Miranda C; El-Kassis EG; Reyes-Leyva J; Sedeño-Monge V
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.
    Lublin FD; Cofield SS; Cutter GR; Gustafson T; Krieger S; Narayana PA; Nelson F; Salter AR; Wolinsky JS
    Mult Scler Relat Disord; 2017 Nov; 18():95-102. PubMed ID: 29141831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice.
    Mitsikostas D; Bakirtzis C; Nikolaidis I; Tsimourtou V; Kountra P; Matsi S; Papadimitriou A
    Neurodegener Dis Manag; 2022 Dec; 12(6):311-322. PubMed ID: 36178000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-β and Glatiramer Acetate.
    Ebrahimi Monfared M; Shapoori S; Mosayebi G; Khansarinejad B; Ghazavi A; Rezagholizamenjany M; Ganji A
    Neuroimmunomodulation; 2019; 26(6):301-306. PubMed ID: 31935737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients.
    Casanova B; Lacruz L; Villar ML; Domínguez JA; Gadea MC; Gascón F; Mallada J; Hervás D; Simó-Castelló M; Álvarez-Cermeño JC; Calles C; Olascoaga J; Ramió-Torrentà L; Alcalá C; Cervelló A; Boscá I; Pérez-Mirallles FC; Coret F
    Neurol Sci; 2018 Aug; 39(8):1423-1430. PubMed ID: 29882169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
    Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
    Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
    J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
    Matute-Blanch C; Río J; Villar LM; Midaglia L; Malhotra S; Álvarez-Cermeño JC; Vidal-Jordana A; Montalban X; Comabella M
    J Neuroimmunol; 2017 Feb; 303():62-65. PubMed ID: 28063616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.